nad and glp 1 GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms Premier - GLP-1 and NAD+
Description
The STEP 1 trial (Wilding et al., 2021), one of the largest studies on semaglutide, found that 39% of the weight lost over 68 weeks was lean mass
In the GLP-1 group, 76 of 145, 410 people developed thyroid cancer, and in the DPP4 group, 184 of 291, 667 developed the disease
Appealing a health plan decision. U.S
1 The mean time from gastric bypass to documented hypoglycemia is about 28 months
Combined Effect: Taking both medications might exacerbate these GI symptoms, making them more challenging to manage and potentially leading to dehydration or nutritional issues
